Trump touts new drug-price deals, seeking a midterm edge

Nine pharmaceutical companies have agreed to lower prices on certain drugs through Trump's Most Favored Nation program, a move that highlights his administration's efforts to control healthcare costs. This initiative could bolster Trump's campaign for the upcoming midterm elections by framing him as a champion for lowering prescription costs, a key issue for many voters. However, critics argue that these deals might not fully address the broader concerns of drug affordability and could divert attention from systemic healthcare reform. This development underscores the ongoing debate about pharmaceutical pricing and its impact on public health and election politics.